3349 COSMOS Pharmaceutical Corporation - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

3349

TSE Prime

COSMOS Pharmaceutical Corporation

9,233

JPY

+13

(+0.14%)

May 2, 3:30 pm JST

63.61

USD

May 2, 2:30 am EDT

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
May, 2021	726,424	33,147	35,835	27,156	342.9	35	Jul 12, 2021	J-GAAP
May, 2022	755,414	29,796	32,861	23,155	292.4	40	Jul 11, 2022	J-GAAP
May, 2023	827,697	30,128	33,086	23,797	300.5	50	Jul 10, 2023	J-GAAP
May, 2024	964,989	31,501	34,299	24,454	308.6	60	Jul 12, 2024	J-GAAP
May, 2025 Guidance	1,037,000	31,600	34,400	24,500	309.1	65	Jul 12, 2024	J-GAAP
YoY	+7.5%	+0.3%	+0.3%	+0.2%	+0.2%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
May, 2020	Jul 12, 2019	658,500	24,800	27,300	19,190	25	J-GAAP
Results	Jul 10, 2020	684,403	29,094	31,562	21,435	27.5	J-GAAP
May, 2021	Jul 10, 2020	Available in future release
Results	Jul 12, 2021
May, 2022	Jul 12, 2021
Results	Jul 11, 2022
May, 2023	Jul 11, 2022
Results	Jul 10, 2023
May, 2024	Jul 10, 2023
Results	Jul 12, 2024
May, 2025	Jul 12, 2024	1,037,000	31,600	34,400	24,500	65*	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
May, 2001	12,396	－	Available in future release
May, 2002	22,524	+81.7
May, 2003	42,413	+88.3
May, 2004	59,413	+40.1
May, 2005	78,651	+32.4
May, 2006	105,046	+33.6
May, 2007	125,846	+19.8
May, 2008	148,244	+17.8
May, 2009	177,756	+19.9
May, 2010	205,387	+15.5
May, 2011	237,174	+15.5
May, 2012	279,021	+17.6
May, 2013	329,313	+18.0
May, 2014	371,825	+12.9
May, 2015	408,466	+9.9
May, 2016	447,273	+9.5
May, 2017	502,732	+12.4
May, 2018	557,999	+11.0
May, 2019	611,137	+9.5
May, 2020	684,403	+12.0
May, 2021	726,424	+6.1
May, 2022	755,414	+4.0
May, 2023	827,697	+9.6
May, 2024	964,989	+16.6
May, 2025 Guidance	1,037,000	+7.5	31,600	+0.3	34,400	+0.3	309.1	+0.2

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
May, 2023	827,697	30,128	3.64	11.85	6.07	2.11	300.5
May, 2024	964,989	31,501	3.26	11.05	5.45	2.15	308.6
May, 2025 Guidance	1,037,000	31,600	3.05	9.85	5.17	2.19	309.1

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	964,989	33,147	35,835	27,156	342.9
Fiscal Year	May, 2024	May, 2021	May, 2021	May, 2021	May, 2021

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec - May, 2021	384,276	14,817	16,367	11,910	150.4	20	Jul 11, 2022	J-GAAP
Dec - May, 2022	423,681	14,743	16,186	12,498	157.8	28.75	Jul 10, 2023	J-GAAP
Dec - May, 2023	488,559	15,665	16,953	12,867	162.4	30	Jul 12, 2024	J-GAAP
Dec - May, 2024 Guidance	531,064	11,256	12,623	10,072	127.1	32.50	Jan 10, 2025	J-GAAP
YoY	+8.7%	-28.1%	-25.5%	-21.7%	-21.7%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
May, 2022	29,796	-11,523	32,194	-43,717	-6,222	37,362	10.29	J-GAAP
May, 2023	30,128	5,321	54,434	-49,113	3,245	45,928	10.91	J-GAAP
May, 2024	31,501	-2,154	55,175	-57,329	8,527	52,301	10.98	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jun - Feb, 2022	606,302	22,167	24,393	16,283	205.6	73.7	Apr 10, 2023	J-GAAP
Jun - Feb, 2023	715,311	23,738	25,914	17,357	219.1	75.6	Apr 12, 2024	J-GAAP
Jun - Feb, 2024	752,268	31,627	33,771	22,343	281.9	98.2	Apr 14, 2025	J-GAAP
YoY	+5.2%	+33.2%	+30.3%	+28.7%	+28.7%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Mar - May, 2023	221,395	7,961	8,693	7,514	94.9	3.6	Jul 10, 2023	J-GAAP
Jun - Aug, 2023	241,653	8,990	9,699	6,508	82.2	3.7	Oct 11, 2023	J-GAAP
Sep - Nov, 2023	234,777	6,846	7,647	5,079	64.1	2.9	Jan 12, 2024	J-GAAP
Dec - Feb, 2023	238,881	7,902	8,568	5,770	72.8	3.3	Apr 12, 2024	J-GAAP
Mar - May, 2024	249,678	7,763	8,385	7,097	89.6	3.1	Jul 12, 2024	J-GAAP
Jun - Aug, 2024	261,841	11,580	12,293	8,143	102.7	4.4	Oct 11, 2024	J-GAAP
Sep - Nov, 2024	244,095	8,764	9,484	6,285	79.3	3.6	Jan 10, 2025	J-GAAP
Dec - Feb, 2024	246,332	11,283	11,994	7,915	99.9	4.6	Apr 14, 2025	J-GAAP
YoY	+3.1%	+42.8%	+40.0%	+37.2%	+37.1%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar - May, 2020	191,526	+19.2	Available in future release
Jun - Aug, 2020	189,161	+15.0
Sep - Nov, 2020	175,014	+8.9
Dec - Feb, 2020	177,522	+5.9
Mar - May, 2021	184,727	-3.5
Jun - Aug, 2021	189,409	+0.1
Sep - Nov, 2021	181,729	+3.8
Dec - Feb, 2021	187,747	+5.8
Mar - May, 2022	196,529	+6.4
Jun - Aug, 2022	206,122	+8.8
Sep - Nov, 2022	197,894	+8.9
Dec - Feb, 2022	202,286	+7.7
Mar - May, 2023	221,395	+12.7
Jun - Aug, 2023	241,653	+17.2
Sep - Nov, 2023	234,777	+18.6
Dec - Feb, 2023	238,881	+18.1
Mar - May, 2024	249,678	+12.8
Jun - Aug, 2024	261,841	+8.4
Sep - Nov, 2024	244,095	+4.0
Dec - Feb, 2024	246,332	+3.1	11,283	+42.8	11,994	+40.0	99.9	+37.2

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	261,841	11,580	12,293	8,509	107.4
Fiscal Year	Aug, 2024	Aug, 2024	Aug, 2024	Feb, 2020	Feb, 2020

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
May, 2022	4,810.92	52.5	363,052	190,507	181,954	0.05	Jul 11, 2022	J-GAAP
May, 2023	5,330.26	50.1	420,967	211,072	202,485	0.09	Jul 10, 2023	J-GAAP
May, 2024	5,840.26	48.6	476,546	231,442	222,284	0.12	Jul 12, 2024	J-GAAP
Jun - Feb, 2024	ー	52.5	474,101	248,822	239,674	0.11	Apr 14, 2025	J-GAAP

COSMOS Pharmaceutical Corporation(3349) Financial Results